The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cn19:09 ET

Chao News | The Breitling boutique in Taikoo Li, Shanghai opens; JNBY "Art Education" launches its first class in Shanghai; Tickets for the 2025 F1 Heineken NV Sponsored ADR Chinese Grand Prix are now on sale; GENTLE MONSTER's flagship store in Xintiandi,

The new Breitling store invites Consumers to experience the diversity presented by "land, sea, and air," as well as the adventurous spirit and vitality of breaking conventions.

cls.cnDec 24 19:24 ET

Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.

①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.

cls.cnDec 1 22:01 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

After consecutive years of losses, "abandoned"? Guangxi Wuzhou Zhongheng Group plans to transfer control of Chongqing Lummy Pharmaceutical | Quick Read Announcement.

①Guangxi Wuzhou Zhongheng Group plans to transfer the shares of Chongqing Lummy Pharmaceutical held directly by the company through public solicitation, which may lead to changes in the controlling shareholder and actual controller of the latter. ②The "story" of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019, and the following April it became the major shareholder of Chongqing Lummy Pharmaceutical, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous state of losses.

cls.cnNov 26 09:55 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET